Back to Treatments

Treatment

Concurrent Chemoradiotherapy (Cisplatin-based)

1
Conditions
12
Trials
30K
Participants
25%
Average Safety

Condition Evidence

Nasopharynx cancer

12 trials · 30K participants

85% effectiveness · 25% safety
Concurrent Chemoradiotherapy (Cisplatin-based) | DFDA